Perspectives of Glaucoma Treatment by Potentiation of a Beta-Agonist
Terbutaline, a selective adrenergic agonist for beta2-receptors, significantly reduces IOP both in the rabbit and in man without producing unwanted side effects. Its efficacy, however, is insufficient for use in glaucoma therapy.
The association of the drug with low-dose guanethidine produces a manifold potentiation of its IOP-lowering effect.
In patients suffering from open-angle glaucoma, the association of 0.5–0.3% guanethidine and 0.3–0.1% terbutaline produces a 21-23% pressure reduction without affecting pupil, accomodation, blood pressure or heart rate.
Its local tolerance is very good.
The potentiation of a beta2-agonist by means of association with low-dose guanethidine would therefore appear to offer sound prospects in terms of future clinical use in glaucoma therapy.
Unable to display preview. Download preview PDF.
- 2.Bonomi L (1954) Sull’azione dell’aleudrina sull’ occhio umano normale. Boll Ocul 43:412–420Google Scholar
- 5.Bonomi L, Perfetti S, Bellucci R, Massa F (1982) Effects of terbutaline on experimentally induced ocular hypertension in the rabbit. Glaucoma 4:134–138Google Scholar
- 7.Bonomi L, Tomazzoli L, Jaria D (1976) An improved model of experimentally induced ocular hypertension in rabbit. Invest Ophthalmol 15: 701–784Google Scholar